Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07609914 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

StatusRecruiting
PhasePhase 4
SponsorPfizer
Started2026-05-28
View on ClinicalTrials.gov ↗
Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack. The primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.

Amendment history 4 changes detected by DataLookout

2026-08-25
minor
Trial sites expanded: 11 → 14 locations
2026-07-30
minor
Trial sites expanded: 7 → 11 locations
2026-07-02
minor
Trial sites expanded: 3 → 6 locations
2026-06-10
notable
Recruitment opened
Trial Details
NCT Number NCT07609914
Lead Sponsor Pfizer
Conditions Acute Treatment of Migraine
Enrollment 400 participants
Start Date 2026-05-28
Primary Completion 2028-05-15 (estimated)
Study Completion 2028-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-24